دورية أكاديمية
Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis.
| العنوان: | Risk of renal impairment in atypical antipsychotics: a systematic review and meta-analysis. |
|---|---|
| المؤلفون: | Ong LT; Faculty of Medicine, University of Malaya, Wilayah Persekutuan Kuala Lumpur, 50603, Kuala Lumpur, Malaysia. leotungong@gmail.com., Chee NMZ; Faculty of Medicine, University of Malaya, Wilayah Persekutuan Kuala Lumpur, 50603, Kuala Lumpur, Malaysia., Loh AJC; Faculty of Medicine, University of Malaya, Wilayah Persekutuan Kuala Lumpur, 50603, Kuala Lumpur, Malaysia. |
| المصدر: | European journal of clinical pharmacology [Eur J Clin Pharmacol] 2024 Jun 25. Date of Electronic Publication: 2024 Jun 25. |
| Publication Model: | Ahead of Print |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Berlin, New York, Springer. |
| مستخلص: | Purpose: Atypical antipsychotics are associated with several adverse effects including metabolic syndrome, weight gain, QTc interval prolongation, and extrapyramidal effects. This study aims to investigate the risk of renal impairment in patients receiving atypical antipsychotics. Methods: A systematic literature search was conducted via PubMed and Ovid SP and Web of Science to retrieve studies reporting the risk of renal impairment in patients receiving atypical antipsychotic treatment. The pooled risk ratio (RR) of renal impairment and the subgroup analysis was calculated using the random-effects generic inverse variance method in Cochrane Review Manager. Results: A total of 4 studies involving 514,710 patients (221, 873 patients on atypical antipsychotics/CKD and 292, 837 controls) were included in this meta-analysis. Patients on atypical antipsychotics exhibited an increased risk of renal impairment, with a pooled risk ratio of 1.34 (95%CI 1.23-1.47). Subgroup analysis demonstrated that atypical antipsychotic use was associated with an increased risk of both acute kidney injury (AKI) (RR 1.51, 95%CI 1.34-1.71) and chronic kidney disease (CKD) (RR: 1.23, 95%CI 1.12-1.35). Conclusion: Patients receiving atypical antipsychotics have an increased risk of renal impairment. Quetiapine carries the highest risk of renal impairment encompassing both AKI and CKD. (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.) |
| References: | Marston L, Nazareth I, Petersen I, Walters K, Osborn DP (2014) Prescribing of antipsychotics in UK primary care: a cohort study. BMJ Open 4(12):e006135. https://doi.org/10.1136/bmjopen-2014-006135. (PMID: 10.1136/bmjopen-2014-006135255245444281533) Badcock JC, Larøi F, Kamp K, Kelsall-Foreman I, Bucks RS, Weinborn M, Begemann M, Taylor JP, Collerton D, O’Brien JT, El Haj M, Ffytche D, Sommer IE (2020) Hallucinations in older adults: a practical review. Schizophr Bull 46(6):1382–1395. https://doi.org/10.1093/schbul/sbaa073. (PMID: 10.1093/schbul/sbaa073326380127707075) Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Pearson SA, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Bachmann CJ (2017) International trends in antipsychotic use: a study in 16 countries, 2005–2014. Eur Neuropsychopharmacol 27(10):1064–1076. https://doi.org/10.1016/j.euroneuro.2017.07.001. (PMID: 10.1016/j.euroneuro.2017.07.00128755801) Roberts R, Neasham A, Lambrinudi C, Khan A (2018) A quantitative analysis of antipsychotic prescribing trends for the treatment of schizophrenia in England and Wales. JRSM Open 9(4):2054270418758570. https://doi.org/10.1177/2054270418758570. (PMID: 10.1177/2054270418758570297072255912284) Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47(1):27–38. (PMID: 10.1177/07067437020470010611873706) Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (2012) Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 17(12):1206–1227. https://doi.org/10.1038/mp.2012.47. (PMID: 10.1038/mp.2012.4722584864) Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17(2):97–107. https://doi.org/10.1016/j.molmed.2010.10.010. (PMID: 10.1016/j.molmed.2010.10.01021185230) Salvi V, Barone-Adesi F, D’Ambrosio V, Albert U, Maina G (2016) High H1-affinity antidepressants and risk of metabolic syndrome in bipolar disorder. Psychopharmacology 233(1):49–56. https://doi.org/10.1007/s00213-015-4085-9. (PMID: 10.1007/s00213-015-4085-926407602) De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114–126. https://doi.org/10.1038/nrendo.2011.156. (PMID: 10.1038/nrendo.2011.156) Correll CU (2008) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47(1):9–20. https://doi.org/10.1097/chi.0b013e31815b5cb1. (PMID: 10.1097/chi.0b013e31815b5cb118174821) Damba JJ, Bodenstein K, Lavin P, Drury J, Sekhon H, Renoux C, Trinh E, Rej S, Greenway KT (2022) Psychotropic drugs and adverse kidney effects: a systematic review of the past decade of research. CNS Drugs 36(10):1049–1077. https://doi.org/10.1007/s40263-022-00952-y. (PMID: 10.1007/s40263-022-00952-y36161425) Jiang Y, McCombs JS, Park SH (2017) A retrospective cohort study of acute kidney injury risk associated with antipsychotics. CNS Drugs 31(4):319–326. https://doi.org/10.1007/s40263-017-0421-4. (PMID: 10.1007/s40263-017-0421-428290080) Hwang YJ, Dixon SN, Reiss JP, Wald R, Parikh CR, Gandhi S, Shariff SZ, Pannu N, Nash DM, Rehman F, Garg AX (2014) Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med 161(4):242–248. https://doi.org/10.7326/m13-2796. (PMID: 10.7326/m13-279625133360) Nian-Sheng T, Yung-Ho H, Shinn-Ying H, Yu-Ching K, Hua-Chin L, Yun-Ju Y, Hong-An C, Wen-Liang C, William Cheng-Chung C, Hui-Ling H (2015) Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study BMJ Open 5(1):e006777. https://doi.org/10.1136/bmjopen-2014-006777. (PMID: 10.1136/bmjopen-2014-006777) Hsien-Yi W, Charles Lung-Cheng H, Feng IJ, Hui-Chun T (2018) Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case–control study. BMJ Open 8(5):e019868. https://doi.org/10.1136/bmjopen-2017-019868. (PMID: 10.1136/bmjopen-2017-019868) Cohen R, Wilkins KM, Ostroff R, Tampi RR (2007) Olanzapine and acute urinary retention in two geriatric patients. Am J Geriatr Pharmacother 5(3):241–246. https://doi.org/10.1016/j.amjopharm.2007.09.003. (PMID: 10.1016/j.amjopharm.2007.09.00317996664) Johnson D, Philip AZ, Joseph DJ, Varghese R (2007) Risperidone-induced neuroleptic malignant syndrome in neurodegenerative disease: a case report. Prim Care Companion J Clin Psychiatry 9(3):237–238. https://doi.org/10.4088/pcc.v09n0311f. (PMID: 10.4088/pcc.v09n0311f176326631911173) Ahuja N, Palanichamy N, Mackin P, Lloyd A (2010) Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. J Psychopharmacol 24(1):125–130. https://doi.org/10.1177/0269881108096901. (PMID: 10.1177/026988110809690118801826) Højlund M, Lund LC, Herping JLE, Haastrup MB, Damkier P, Henriksen DP (2020) Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study. BMJ Open 10(8):e038247. https://doi.org/10.1136/bmjopen-2020-038247. (PMID: 10.1136/bmjopen-2020-038247327842627418669) El-Saifi N, Moyle W, Jones C, Tuffaha H (2016) Quetiapine safety in older adults: a systematic literature review. J Clin Pharm Ther 41(1):7–18. https://doi.org/10.1111/jcpt.12357. (PMID: 10.1111/jcpt.1235726813985) Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Retrieved from https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp on 1st Decemeber 2023. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188. https://doi.org/10.1016/0197-2456(86)90046-2. (PMID: 10.1016/0197-2456(86)90046-23802833) Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928. (PMID: 10.1136/bmj.d5928220082173196245) Review Manager (RevMan) (2020) [Computer program]. Version 5.4.1 The Cochrane Collaboration. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. https://doi.org/10.1136/bmj.b2535. (PMID: 10.1136/bmj.b2535196225512714657) Ryan PB, Schuemie MJ, Ramcharran D, Stang PE (2017) Atypical antipsychotics and the risks of acute kidney injury and related outcomes among older adults: a replication analysis and an evaluation of adapted confounding control strategies. Drugs Aging 34(3):211–219. https://doi.org/10.1007/s40266-016-0430-x. (PMID: 10.1007/s40266-016-0430-x28124262) Wang HY, Huang CL, Feng IJ, Tsuang HC (2018) Second-generation antipsychotic medications and risk of chronic kidney disease in schizophrenia: population-based nested case-control study. BMJ Open 8(5):e019868. https://doi.org/10.1136/bmjopen-2017-019868. (PMID: 10.1136/bmjopen-2017-019868297940905988075) Sharon R, Lange T, Aakjær M, Brøgger Kristiansen S, Baltzer Houlind M, Andersen M (2022) Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study. Eur J Clin Pharmacol 78(8):1341–1349. https://doi.org/10.1007/s00228-022-03339-6. (PMID: 10.1007/s00228-022-03339-6356391329283184) Correll CU, Detraux J, De Lepeleire J, De Hert M (2015) Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 14(2):119–136. https://doi.org/10.1002/wps.20204. (PMID: 10.1002/wps.20204260433214471960) Tzeng NS, Hsu YH, Ho SY, Kuo YC, Lee HC, Yin YJ, Chen HA, Chen WL, Chu WC, Huang HL (2015) Is schizophrenia associated with an increased risk of chronic kidney disease? A nationwide matched-cohort study BMJ Open 5(1):e006777. https://doi.org/10.1136/bmjopen-2014-006777. (PMID: 10.1136/bmjopen-2014-00677725628048) Tzur Bitan D, Krieger I, Berkovitch A, Comaneshter D, Cohen A (2019) Chronic kidney disease in adults with schizophrenia: a nationwide population-based study. Gen Hosp Psychiatry 58:1–6. https://doi.org/10.1016/j.genhosppsych.2019.01.007. (PMID: 10.1016/j.genhosppsych.2019.01.00730807892) Rabins PV, Lyketsos CG (2005) Antipsychotic drugs in dementia: what should be made of the risks? JAMA 294(15):1963–1965. https://doi.org/10.1001/jama.294.15.1963. (PMID: 10.1001/jama.294.15.196316234504) Romagnani P, Remuzzi G, Glassock R, Levin A, Jager KJ, Tonelli M, Massy Z, Wanner C, Anders HJ (2017) Chronic kidney disease. Nat Rev Dis Primers 3:17088. https://doi.org/10.1038/nrdp.2017.88. (PMID: 10.1038/nrdp.2017.8829168475) Silveira Santos CGD, Romani RF, Benvenutti R, Ribas Zahdi JO, Riella MC, Mazza do Nascimento M (2018) Acute kidney injury in elderly population: a prospective observational study. Nephron 138(2):104–112. https://doi.org/10.1159/000481181. (PMID: 10.1159/00048118129169177) Kirkham J, Seitz D (2015) New use of antipsychotics associated with a small increased risk of acute kidney injury in older adults with mental disorders. Evid Based Ment Health 18(2):55. https://doi.org/10.1136/eb-2014-101979. (PMID: 10.1136/eb-2014-10197925743449) |
| فهرسة مساهمة: | Keywords: Acute kidney injury; Antipsychotic; Chronic kidney disease; Psychiatric disorders |
| تواريخ الأحداث: | Date Created: 20240625 Latest Revision: 20240625 |
| رمز التحديث: | 20240625 |
| DOI: | 10.1007/s00228-024-03714-5 |
| PMID: | 38916726 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1432-1041 |
|---|---|
| DOI: | 10.1007/s00228-024-03714-5 |